You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Harvard Business School
Medtronic
Boehringer Ingelheim
Colorcon

Last Updated: August 8, 2020

DrugPatentWatch Database Preview

Valeant Pharms North Company Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for VALEANT PHARMS NORTH, and what generic alternatives to VALEANT PHARMS NORTH drugs are available?

VALEANT PHARMS NORTH has eighteen approved drugs.

There are ten US patents protecting VALEANT PHARMS NORTH drugs.

There are fifty-three patent family members on VALEANT PHARMS NORTH drugs in eighteen countries and thirty-three supplementary protection certificates in fifteen countries.

Summary for Valeant Pharms North
International Patents:53
US Patents:10
Tradenames:15
Ingredients:14
NDAs:18

Drugs and US Patents for Valeant Pharms North

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharms North RENOVA tretinoin CREAM;TOPICAL 021108-001 Aug 31, 2000 RX Yes Yes 6,531,141   Start Trial   Start Trial
Valeant Pharms North MINITRAN nitroglycerin FILM, EXTENDED RELEASE;TRANSDERMAL 089772-001 Aug 30, 1996 DISCN No No   Start Trial   Start Trial
Valeant Pharms North NIFEDIPINE nifedipine TABLET, EXTENDED RELEASE;ORAL 075269-002 Dec 4, 2000 AB1 RX No No   Start Trial   Start Trial
Valeant Pharms North APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-003 Apr 23, 2008 RX Yes Yes 7,649,019   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Valeant Pharms North

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharms North PEPCID famotidine TABLET;ORAL 019462-001 Oct 15, 1986 4,283,408*PED   Start Trial
Valeant Pharms North RENOVA tretinoin CREAM;TOPICAL 019963-001 Dec 29, 1995 4,603,146   Start Trial
Valeant Pharms North CARAC fluorouracil CREAM;TOPICAL 020985-001 Oct 27, 2000 4,690,825   Start Trial
Valeant Pharms North PEPCID famotidine TABLET;ORAL 019462-002 Oct 15, 1986 4,283,408*PED   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for VALEANT PHARMS NORTH drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Cream 0.5% ➤ Subscribe 2011-07-29
➤ Subscribe Extended-release Tablets 348 mg ➤ Subscribe 2009-09-24
➤ Subscribe Extended-release Tablets 174 mg ➤ Subscribe 2009-09-28
➤ Subscribe Extended-release Tablets 522 mg ➤ Subscribe 2009-12-24

Supplementary Protection Certificates for Valeant Pharms North Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1304992 2013/044 Ireland   Start Trial PRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322
0617614 2001/009 Ireland   Start Trial PRODUCT NAME: PANRETIN-ALITRETINOIN
1304992 CR 2013 00053 Denmark   Start Trial PRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
1304992 C300617 Netherlands   Start Trial PRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Medtronic
Mallinckrodt
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.